Drug Profile
Research programme: metabolic disorder therapeutics - Acquist Therapeutics
Alternative Names: RLBN 1001; RLBN 11127; RLBN 1133; RLBN 2020 series; RLBN 3010 seriesLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Relburn Metabolomics
- Developer Acquist Therapeutics
- Class Antigouts; Hepatoprotectants; Small molecules; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors; Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gout; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Gout in USA
- 28 Nov 2021 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 17 Jan 2019 Acquist Therapeutics has patent protection for compounds intended for treatment of patients with NASH, gout, and other illnesses in USA